Brontel

Quick links to important sections

Brontel

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Brontel

This section defines Brontel by its identity, composition, class, and general purpose, strictly excluding details on specific treatment indications, dosages, or safety information.

Quick Facts Description
Active ingredient Clenbuterol Hydrochloride
Form Tablets, Syrup, Oral solution
Pharmacological class Selective beta2-adrenergic agonist
Common purpose Relief of airway constriction
Origin Synthetic compound

What Type of Medicine is Brontel and What is its Composition?

Brontel is a synthetic, single-ingredient medicine classified as a sympathomimetic agent and a selective long-acting beta2-adrenergic agonist (LABA). The drug's efficacy is derived from its sole active substance, Clenbuterol Hydrochloride.

This medication's identity stems from its specific chemical structure, which grants it the precision to selectively target specific receptors in the respiratory system. It is clinically recognized for its long duration of action. The oral administration route allows the active compound to be absorbed systemically. Brontel is specifically available as Syrup and Oral solution in some regions, a feature that differentiates its administration from inhaled bronchodilators and provides an option often preferred for the pediatric patient group.

The Pharmacological Action and General Purpose of Clenbuterol

The core function of Clenbuterol is to act as a bronchodilator, achieving the general purpose of reducing airway obstruction. A typical use scenario involves providing support during periods of breathing difficulty caused by constricted air passages.

This action is achieved by the drug selectively binding to and activating the beta2-adrenoreceptors, which initiates a process that causes the smooth muscle lining the bronchial tubes to relax. This mechanism directly alleviates difficulty in breathing by widening constricted airways. The result, known as bronchodilation, is a physical widening of the air passages. Therefore, the medication’s core physiological purpose is to counteract the physical narrowing of the respiratory system, serving to ease the general effort required for ventilation and improving airflow.

What side effects are possible with Brontel?

Possible Side Effects and Safety Information

The official safety profile for Brontel (Clenbuterol Hydrochloride), consistent with its classification as a selective beta2-adrenergic agonist, focuses on effects related to sympathetic nervous system stimulation.


Adverse Reaction Classification

The documented core adverse reactions are classified as Rare in official product labeling. These effects generally stem from the drug's activity on the cardiac and nervous systems. They are also noted to be temporary and dose-related.

System-Organ Class Officially Documented Adverse Reactions
Nervous System Disorders Muscle tremor, Nervousness, Restlessness
Cardiac Disorders Tachycardia (increased heart rate), Disturbances of the heart rhythm (Arrhythmias)
Vascular Disorders Slight hypotension
Skin Disorders Sweating

Serious adverse reactions, such as disturbances of the heart rhythm (Arrhythmias), are documented as risks, particularly under specific clinical circumstances. This medicine is formally contraindicated in individuals with known cardiac disease and in cases of documented hypersensitivity to the active ingredient.


Population-Specific Safety Notes

A specific regulatory caution exists regarding use during pregnancy. Due to its potential to abolish uterine contractions, treatment should be discontinued at the expected time of delivery. Furthermore, high-level safety notes indicate that the effects of Clenbuterol may be reduced by beta-blockers, and there is a documented risk of increased side effects when co-administered with other sympathomimetics, glucocorticoids, or methylxanthines.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Brontel (Clenbuterol Hydrochloride) classifies overdose as an event associated with severe sympathomimetic toxicity, which mandates immediate medical attention.

Documented Overdose Manifestations

Overdose presentations are documented to include Tachycardia (rapid heart rate), Muscle Tremor, Restlessness, Diaphoresis (sweating), Nausea, Vomiting, Headache, and Hypotension. Physiologically, the affected systems include the Cardiovascular, Neurological, and Metabolic systems. Severe manifestations are formally documented as profound Hypokalemia, Hyperglycemia, and Lactic Acidosis. The documented risk profile also extends to Pediatric and adolescent patients, or those with accidental exposure from contaminated sources.

Emergency Action and Procedural Response

Regulatory documents explicitly state that immediate medical attention must be sought for any suspected overdose or ingestion exceeding the usual single therapeutic dose. Urgent help is required for the onset of severe symptoms like chest pain, severe palpitations, or persistent agitation. Given the potential for life-threatening outcomes such as Tachyarrhythmias and Myocardial Ischemia, Hospitalization and Continuous Cardiac Monitoring are required. Management is documented as symptomatic and supportive treatment, with a β-blocker being listed as a potential antidote.

Therapeutic Uses of Brontel

What Brontel treats: Main Uses and Benefits

Easing Sudden Breathing Difficulty and Airway Tightness

Brontel is a supportive medication relevant for managing symptoms across certain obstructive airway conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD). This class of medication may be part of symptomatic management when patients experience symptoms related to heightened physiological activity that cause functional strain. The medication is commonly used during acute episodes to ease sudden manifestations like breathlessness, wheezing, or chest tightness, and in the supportive management of persistent respiratory conditions. This assistance helps patients cope more steadily with difficult episodes.

Improving Functional Stability and Activity Tolerance

The medication assists with assisting with maintaining functional stability and supports the patient during difficult episodes by easing distress during symptomatic phases. Applied in scenarios where symptoms interfere with daily functioning, it contributes to easing the overall symptom load by addressing symptom clusters that become disruptive during flare-ups.

Quick Fact: Relief for Sudden and Persistent Breathing Discomfort

Regulatory References

  1. NIH National Library of Medicine on Bronchodilators

Eligibility and Restrictions for Use

Who Can and Cannot Use Brontel?

The official eligibility profile for Brontel (Clenbuterol Hydrochloride) is strictly defined by regulatory labeling from authorizing health agencies. Use is established in adults for the management of conditions such as Bronchial Asthma and Chronic Obstructive Pulmonary Disease (COPD) in authorized jurisdictions.

Contraindicated Populations

The medicine is subject to several absolute prohibitions. Use is strictly contraindicated for patients with Serious Cardiovascular Disorders, Hyperthyroidism, and confirmed Hypersensitivity to the active substance or related sympathomimetic amines. Some official regulatory documents also prohibit use in patients with Diabetes Mellitus.

Restricted and Not Recommended Use

Official labeling defines restricted populations where use is advised against. The medicine is not recommended for pregnant women or breastfeeding mothers due to limited safety data and risk profiles. Similarly, use in pediatric patients (children and adolescents) is restricted because safety and efficacy are not fully established in this age group. A critical regulatory constraint is that Brontel is unapproved for human therapeutic use by the U.S. Food and Drug Administration (FDA).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Brontel (Clenbuterol Hydrochloride) has documented interaction patterns that primarily involve pharmacodynamic effects, as outlined in regulatory prescribing information. The official profile defines constraints related to opposing therapeutic actions and the potentiation of cardiovascular effects.


Pharmacodynamic and Contraindicated Interactions

Interaction Type Interacting Substances/Classes
Antagonism / Contraindication beta-Adrenergic Blocking Agents (e.g., Atenolol, Bisoprolol), as they oppose the product's primary action.
Potentiation of Effects Other Sympathomimetics, Methylxanthines, Glucocorticoids, and Digitalis Glycosides. Co-administration may enhance effects, including the risk of cardiac arrhythmias.

Interaction-Related Restrictions and Considerations

Co-administration with other beta-adrenergic agents is not permitted due to the risk of enhanced sympathomimetic effects. Regulatory documentation notes a restriction concerning the product's effect on uterine activity. If Brontel is used during pregnancy, treatment must be discontinued a minimum of four days prior to the expected time of delivery, as the medicine can reduce or abolish uterine contractions. The efficacy of certain antihypertensive medicines may also be reduced when co-administered with Brontel.

Mechanism of Action

Brontel is a prodrug (bambuterol) that undergoes enzymatic hydrolysis, primarily in the liver, by butyrylcholinesterase to yield the active metabolite, terbutaline. Terbutaline functions as a selective beta2-adrenergic receptor agonist.

Upon systemic distribution, terbutaline selectively targets beta2-adrenergic receptors located on the smooth muscle cells lining the respiratory tract. The binding event triggers receptor activation, which is coupled to the Gs protein subunit. This coupling initiates the molecular cascade by stimulating the effector enzyme adenylyl cyclase (AC). AC catalyzes the conversion of adenosine triphosphate (ATP) to the second messenger cyclic adenosine monophosphate (cAMP), resulting in an elevation of intracellular cAMP concentration.

Increased cAMP levels activate Protein Kinase A (PKA). PKA then phosphorylates multiple target proteins, including the inhibition of myosin light-chain kinase (MLCK). Inhibition of MLCK prevents the phosphorylation of myosin light chain, which is an essential step for muscle contraction. This downstream molecular consequence leads to the functional relaxation of the airway smooth muscle, resulting in a systemic-level physiological consequence of bronchodilation.

Dosage and Administration Information

How to Use Brontel: Official Administration Guidelines

The usage of Brontel (Clenbuterol Hydrochloride) is defined by a structured protocol.

Feature Guideline
Route of administration The medicine is administered via the oral route (tablets, syrup, or solution) and through inhalation in certain formulations.
Dosing schedule The standard adult regimen begins with 20mu g per administration, taken twice daily. This amount may be adjusted or titrated upward, with official guidelines permitting a maximum daily dose of up to 80mu g.
Frequency and Timing The schedule requires a twice daily (b.i.d.) routine, typically maintaining a 12-hour interval. This frequency supports the drug's long half-life, ensuring a sustained presence in the body.
Population-specific rules Use in pediatric patients requires specialized consultation due to limited official data on optimal dosing schedules for this group.
Contextual constraints Brontel is legally not approved for human therapeutic use in the United States, which is a critical constraint defining its use context in that region.

Resulting Procedural Structure

Official step sequence:

  • Initiate treatment with the 20mu g per-administration dose, selecting the prescribed oral or inhalation route.
  • Administer the dose twice daily, maintaining a consistent dosing interval to reach steady-state concentrations, which typically occurs within 3 to 5 days.
  • If necessary, adjust the dose up to the labeled maximum under a defined protocol.

Connection to the overall use protocol (2–4 sentences): The official usage protocol dictates a structured, twice-daily administration designed to achieve sustained systemic exposure to the active substance, utilizing the oral or inhalation route. This framework strictly defines the labeled dose limits and the necessary frequency, establishing the mandatory procedural steps for the drug’s proper use.

Recent Clinical Evidence

Research evidence / Overview of studies for Brontel

Evidence for Use in Managing Reversible Airway Obstruction

Brontel (Clenbuterol Hydrochloride) was studied for its use in conditions associated with constricted air passages, such as asthma. Research primarily involved short-term Randomized Controlled Trials (RCTs) and cross-over comparison studies. These research scenarios monitored responses over defined time intervals and were designed to evaluate the medicine's immediate, measurable physiological characteristics.

Research reports from studies indicate patterns of physiological changes measured in FEV1 and PEFR across the study populations following administration. Specifically, the data show patterns related to measured increases in air flow, which were observed during the study period compared to a placebo or other active medicines.

Research on the Duration of Action and Protective Effect

Beyond simple measurement of air passage widening, research also examined the medicine’s duration of action. These comparison studies explored the medicine's ability to maintain its measured effect over several hours, which is relevant in trials assessing short-term or episodic symptom patterns. The findings indicate that the duration of measured effect was studied in comparison to certain other quick-acting bronchodilators, thus contributing to the broader evidence landscape related to its classification as a long-acting agent.

Furthermore, studies explored its use for prophylactic protection, which means research explored its potential role in addressing temporary constriction, such as that caused by exercise. This research describes the ability of the substance to provide a measurable degree of protection for a defined time against an induced physiological challenge.

Long-Term Research and the Durability of Response

Available research for the medicine focuses predominantly on the initial and short-term response. Follow-up durations were limited in many primary trials, meaning the long-term effects are not fully established. Scientific literature has also explored whether the physiological response might lessen with continuous, long-term use, a phenomenon known as tachyphylaxis. This area represents a research gap; certainty remains low regarding the medicine's effects during prolonged daily administration.

Research Evidence in Specific Patient Groups

Studies indicate that Brontel was evaluated in both adult and pediatric patients who presented with obstructive airway conditions. For children, studies explored the use of the oral formulations (syrup/solution) which are relevant in trials assessing short-term symptom patterns in that specific group. Data for certain groups remain insufficient, and research does not determine whether an individual outside the studied population will respond similarly.

Understanding the Gaps and Uncertainties in Brontel Research

Key limitations include the fact that follow-up durations were limited in many primary studies, and the evidence quality varies across studies regarding long-term clinical endpoints like hospitalizations or reduction in symptom exacerbations. Therefore, research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Brontel (FAQ)

Q: Is Brontel considered a long-term treatment or just for short-term use?

The official usage protocol for Brontel is structured to support a sustained presence of the active substance in the body through consistent, twice-daily administration. However, regulatory research evidence notes that available data is predominantly from short-term studies. This means that the long-term effects of using Brontel continuously over an extended period are not yet fully established in official documents.

Q: Does Brontel show up on a standard drug test?

Official information indicates that Brontel (Clenbuterol Hydrochloride) is categorized by certain major sports authorities, such as the World Anti-Doping Agency (WADA), as a substance banned from competition. This classification indicates that the substance may be subject to testing protocols in specific regulatory contexts, such as organized sports.

Q: What is the main difference between Brontel and a generic version?

The primary difference between a branded medicine like Brontel and a generic version is the name. According to regulatory standards for medicines, a generic version must contain the exact same active substance—Clenbuterol Hydrochloride—as the branded product. Regulatory standards indicate that a generic version is required to meet the same quality and composition requirements as the branded product.

Q: Do I need to take Brontel at a specific time of day?

Regulatory information specifies that the medicine must be administered twice daily. The schedule is structured around maintaining a consistent time interval between doses to support a sustained presence of the active substance in the body.

Q: Does Brontel affect sleep patterns?

Official safety documents list adverse reactions related to the nervous system, which are often temporary and dose-related. These reactions include nervousness and restlessness. These are effects that originate from the drug's activity on the nervous system.

Q: Is there a different name for Brontel in other countries?

Yes, Brontel is a brand name for the active ingredient Clenbuterol Hydrochloride. This medicine is authorized under various different brand names in other regions, such as Spiropent or Monores.

Q: Does Brontel cause any long-term health issues?

Official research summaries indicate that the follow-up periods in many of the primary studies were limited. Because of this, the official evidence and certainty regarding the medicine's effects during prolonged, continuous administration are not fully established in regulatory documents.

Q: How long does Brontel stay in your system after you stop taking it?

Pharmacological data in official sources indicates that the active substance in Brontel has a relatively long elimination half-life. This long half-life is described in regulatory documents as being approximately 35 hours.

Q: Can taking Brontel affect my ability to drive or operate machinery?

The safety profile for Brontel lists adverse reactions related to the nervous system, such as muscle tremor and feelings of nervousness. Official documents indicate that these possible effects should be considered in the context of performing tasks that require concentration, such as driving or operating machinery.

Q: Is it true that Brontel works better for certain types of people?

Research evidence confirms that studies for Brontel were conducted in both adult and pediatric patient groups with obstructive airway conditions. While data for specific subgroups is described as insufficient, the findings published in official literature generally describe group patterns observed in the studies, not individual predictions or assurances of better outcomes for one specific type of person.

Q: What kind of side effects are generally mild and temporary with Brontel?

Official product labeling notes that the documented core adverse reactions are classified as Rare and are generally considered temporary and dependent on the dose taken. These effects include disturbances like muscle tremor, nervousness, and a slight increase in heart rate.

Q: Are there different strengths of Brontel available?

Yes, official product information from authorizing health agencies confirms that Brontel (Clenbuterol Hydrochloride) is available in different strengths and formulations. For example, some regulatory listings include both 10 mu g and 20 mu g tablets.

Q: Is there any research on Brontel's use during pregnancy?

While the medicine is not recommended for pregnant women, official documentation refers to animal studies that have investigated the substance’s profile. These studies noted that the substance is able to cross the placenta and demonstrated effects on the weight and viability of offspring in the treated groups.

Q: What is the risk of having a serious interaction with Brontel?

Regulatory documents describe constraints on co-administration with several other classes of medicines, such as Sympathomimetics and Methylxanthines. These combinations are noted because they may enhance certain effects, including an increased risk of disturbances to the heart rhythm (cardiac arrhythmias).

Q: Why is Brontel sometimes described as a 'selective' medicine?

Brontel is described as 'selective' because the active substance is designed to primarily target and activate one specific type of receptor in the body: the beta2-adrenergic receptors. These receptors are mainly located on the smooth muscle cells lining the airways, which explains the medicine’s core function.

Q: Why do some people stop taking Brontel?

The official product safety profile documents adverse reactions that are known to occur. These effects include muscle tremor, nervousness, restlessness, and increased heart rate, which are temporary and dose-related effects noted in clinical monitoring.

Q: What is the shelf life of Brontel?

Official storage guidelines detail that the liquid forms of Brontel, such as the Syrup or Oral Solution, have a limited shelf-life after the original container has been opened for the first time. This specific duration, which may be 30 days to 3 months, is defined on the official product labeling.

Q: Is Brontel the same kind of medicine as [similar drug name]?

Brontel is defined by its core pharmacological class as a selective beta2-adrenergic agonist. This means its primary function is to act as a bronchodilator, which is intended to reduce airway constriction and ease breathing difficulties.

Q: How quickly does Brontel start working after you take it?

Pharmacological data from official sources indicates that the active substance in Brontel is rapidly absorbed into the body. Peak concentrations in the blood are generally reached within a window of two to three hours after taking an oral dose.

Q: How long before I can expect the full effect of Brontel?

The official usage protocol defines a structured, twice-daily administration routine that is designed to help the body reach a 'steady-state concentration' of the active substance. This level of sustained presence in the body typically occurs within three to five days after starting the treatment.

Q: What if I accidentally take two doses of Brontel close together?

Official safety documents define a maximum daily dose and note that exceeding the prescribed amount may cause transient side effects typical for this class of medicine, which official documents list as including an increase in heart rate, muscle tremor, and sweating.

How should Brontel be stored and disposed of?

Brontel (Clenbuterol Hydrochloride) must be stored and disposed of according to official regulatory specifications to maintain its stability and ensure public safety.

Official Storage Requirements

Condition Regulatory Mandate
Temperature Store below 25 C or 30 C; do not freeze the liquid form.
Protection Protect from light and moisture by keeping the container in the original packaging.
Handling Keep the bottle or container tightly closed. The Syrup/Oral Solution typically has a limited shelf-life (e.g., 30 days to 3 months) after first opening.
Safety Keep out of the sight and reach of children (a mandatory requirement).

Official Disposal Rules

Disposal of unused or expired Brontel must follow local waste regulations. The medicine must not be discarded via household wastewater or sewage systems. The recommended method for proper disposal is through an authorized pharmacy take-back program or a designated local collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Brontel found in:

A-Z Index: